Metabolic Syndrome as A Prognostic Factor for Outcome of Severe SARS-COV-2 Cases

Abstract

Abstract Background SARS-COV-2 (Coronavirus Disease-2019), a disease caused by the coronavirus. SARS-CoV-2 (Sever Acute Respiratory Syndrome-Coronavirus-2) has emerged as a rapidly spreading communicable disease affecting more than 100 countries across the globe at present. Aim of the Work To illuminate to what extent metabolic syndrome can be used as a prognostic factor for outcomes of patients infected with SARS-COV-2. Primary outcome measure is ICU stay and outcome. Secondary outcome measures are Patients requiring MV and mortality. Patients and Methods This was a retrospective study in order to illuminate to what extent metabolic syndrome can be used as a prognostic factor for outcomes of patients infected with SARS-COV-2, with Primary outcome measure which was ICU stay and outcome, and Secondary outcome measures were Patients requiring MV and mortality. Ninety patients admitted to ICU for Pneumonic COVID-19 with a confirmed positive RT-PCR for COVID-19 and chest computed tomography was divided into two groups in Ain-shams University hospitals. Results Components of metabolic syndrome such as hypertension, type 2 diabetes mellitus (T2DM), and obesity are highly prevalent and significantly increase the risk of hospitalization and mortality in SARS-COV-2 patients. Conclusion MetS is a better prognostic indicator for severe disease outcomes in patients with COVID-19 than its individual components. Patients with MetS had a significantly higher need for ICU admission irrespective of their age, sex, or race. The need for mechanical ventilation was also higher across all patients with MetS. The association of MetS with higher mortality was significant for females, patients younger than 65 years of age.